JAK2

Chr 9

Janus kinase 2

Also known as: JTK10

This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

ResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtBudd-Chiari syndrome
UniProtPolycythemia vera
UniProtThrombocythemia 3
UniProtMyelofibrosis

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
12
Active trials
2352
Pubs (1 yr)
P/LP submissions
P/LP missense
0.34
LOEUF· LoF intol.
Multiple*
Mechanism· predicted
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.34LOEUF
pLI 0.654
Z-score 5.66
OE 0.21 (0.140.34)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
0.90Z-score
OE missense 0.90 (0.830.96)
518 obs / 578.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.21 (0.140.34)
00.351.4
Missense OE?0.90 (0.830.96)
00.61.4
Synonymous OE?1.11
01.21.6
LoF obs/exp: 13 / 60.6Missense obs/exp: 518 / 578.6Syn Z: -1.21

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

JAK2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Insulin ResistanceObesity & OverweightEnergy Metabolism

Effects of Ketone Bodies on Insulin Sensitivity

RECRUITING
NCT07359625Phase NAUniversity of AarhusStarted 2025-12-02
Growth Hormone, HumanOral ketone supplement (KetoAid®, KE4)Saline infusion (placebo)
Aplastic AnemiaTPO Receptor Agonists

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

RECRUITING
NCT06613880Phase PHASE2Institute of Hematology & Blood Diseases Hospital, ChinaStarted 2024-10-24
standard IST combined with Romiplostim N01
Chronic Myeloid Leukemia, Chronic PhaseWithdrawal;Drug

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

ACTIVE NOT RECRUITING
NCT04147533Phase PHASE2Masaryk UniversityStarted 2020-06-16
Imatinib withdrawalDasatinibNilotinib
Acute Myeloid Leukemia (AML)

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

RECRUITING
NCT07464951Phase PHASE1Stephan Grupp MD PhDStarted 2026-05-14
Anti-CD123 LV redirected T cells (CART123)Ruxolitinib (JAKAVI®)
T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

RECRUITING
NCT07356245Phase PHASE2Jonathan BrammerStarted 2026-02-12
RuxolitinibPositron emission tomography-computed tomographyBone Marrow Biopsy
Giant Cell ArteritisTemporal ArteritisClonal Hematopoiesis of Indeterminate Potential

Clonal Hematopoiesis in Giant Cell Arteritis

NOT YET RECRUITING
NCT06244069ASST Fatebenefratelli SaccoStarted 2024-03
Temporal arterial biopsyWhole exome sequencingSingle cell transcriptomics
Clonal HematopoiesisClonal Hematopoiesis of Indeterminate PotentialClonal Cytopenia of Undetermined Significance (CCUS)

CHIP in Health and Disease

NOT YET RECRUITING
NCT07780552VASCage GmbHStarted 2026-10
AML, Adult

MRD-positive AML Clinical Study

RECRUITING
NCT07131059Phase NAInstitute of Hematology & Blood Diseases Hospital, ChinaStarted 2024-05-11
IvosidenibGilteritinibVenetoclax
BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

ACTIVE NOT RECRUITING
NCT03801434Phase PHASE2Stanford UniversityStarted 2019-11-15
Ruxolitinib
Chronic Myelomonocytic Leukemia

Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)

RECRUITING
NCT03280888Centre Hospitalier Universitaire de NiceStarted 2014-11-05
Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
Myelofibrosis,MF

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

RECRUITING
NCT07394153Phase PHASE2Grupo Español de Enfermedades Mieloproliferativas Crónicas PH NegativasStarted 2026-04-15
Pacritinib